With science created at Imperial and Brunel Universities and its development funded by Nc3r’s, Novartis and GSK; Testavec is the only UK company dedicated to analysing and improving the safety and performance of Vectors used for Gene Therapy and CAR-T therapy.
Unique patented assays include – can a patient repair their DNA? Does a Vector cause cancer in HUMAN cells? how contaminated is your vector?
Testavec focuses on RISK Reduction our CSO has more than 25 years experience in Gene Therapy safety testing – Tested by Tesavec reduces risk